Maryland 2026 Regular Session

Maryland Senate Bill SB778

Introduced

2/6/26

Refer

2/6/26

Report Pass

3/19/26

Engrossed

3/20/26

Refer

3/21/26

Report Pass

4/11/26

Enrolled

4/13/26

Chaptered

4/28/26

Passed

4/28/26

Caption

Clinical Research Pharmacies and Clinical Trials - Permits and Ownership

Companion Bills

MD HB1426

Crossfiled Clinical Research Pharmacies and Clinical Trials - Permits and Ownership

Previously Filed As

MD HB1426

Clinical Research Pharmacies and Clinical Trials - Permits, Ownership, and Definition of Practice of Medicine

MD HB1477

Public Health - Ibogaine Clinical Research Grant Program - Establishment (Veterans Mental Health Innovations Act)

MD HB905

Hospitals - Clinical Staffing Committees and Plans - Establishment (Safe Staffing Act of 2025)

MD SB720

Hospitals - Clinical Staffing Committees and Plans - Establishment (Safe Staffing Act of 2025)

MD HB1094

Health Insurance - Graduate-Level Clinical Interns - Required Reimbursement

MD HB1325

Workers' Compensation - Evaluation of Permanent Impairments - Licensed Social Worker-Clinical

MD HB1483

Clinical Professional Counseling and Social Work - Out-of-State Providers - Use of Telehealth for Continuity of Care

MD SB536

Research Facilities and Testing Facilities That Use Animals - Regulation

MD SB306

Workers' Compensation - Prescription Drug and Pharmaceutical Services - Reimbursements

MD SB535

Research Facilities and Testing Facilities That Use Animals - Licensing and Regulations

Similar Bills

MD HB1426

Clinical Research Pharmacies and Clinical Trials - Permits and Ownership

OH SB249

Authorize dispensing of ivermectin without a prescription

TX SB493

Relating to protection of certain disclosures and communications by pharmacists and pharmacies regarding prescription drug benefits.

CT HB07192

An Act Implementing Recommendations Of The Bipartisan Drug Task Force.

OH HB374

Regards prescription drug readers for visually impaired patients

OR HB3046

Relating to pharmacy; prescribing an effective date.

NJ A3406

Establishes prescription drug pricing disclosure requirements and measures to reduce prescription drug costs.

TX SB1098

Relating to the disclosure by a pharmacy to a patient of certain price information for a drug or biological product.